Search results

Radiocarbon dating is a well-known method for determining the age of materials up to the age of approximately 50,000 years.

Imaging protocol assesses molecular mechanism of work in the treatment of deadly childhood cancer neuroblastoma.

Researchers developing new materials and devices that can withstand the harsh radiation environment in space are using the unique ANSTO’s capability to simulate the effects of high-energy ion irradiation on the properties and performance of these materials and devices.

Updated results show radiation therapy using lutetium-177 improved survival in advanced prostate cancer.

ANSTO has been tracking and publishing data on fine particle pollution from key sites around Australia, and internationally, for more than 20 years.  

Research on the mechanism of cell death has insights to bring progress on neurodegenerative diseases and plant biosecurity.

ANSTO’s nuclear medicine processing and distribution facility assembles, loads, tests and distributes a range of nuclear medicine products, including Mo-99. The Mo-99 is dispensed into an ANSTO radiopharmaceutical Gentech® Generator where it decays to Tc-99m.

New research published a team from the Imperial College London, University of Glasgow and ANSTO suggests that rock coasts, which make up over half the world’s coastlines, could retreat more rapidly in the future due to accelerating sea level rise.

Congress marks watershed moment for nuclear medicine and ANSTO

The Advanced Diffraction and Scattering beamlines (ADS-1 and ADS-2) are two independently operating, experimentally flexible beamlines that will use high-energy X-ray diffraction and imaging to characterise the structures of new materials and minerals.

Phase contrast tomography shows great promise in early stages of study and is expected to be tested on first patients by 2020.

The Nobel Prizes for Physics, Chemistry and Medicine have been announced. 

Developed by ANSTO’s predecessor the Australian Atomic Energy Commission (known as the AAEC) in the late 1960s, the Technetium-99m Generator revolutionised nuclear medicine imaging in Australia by enabling imaging procedures to be performed not only in major capital cities but throughout regional and rural Australia.